Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

HROW

Harrow Inc

Dec 06 • 04:00PM ET

9.62

Dollar change +0.22
Percentage change 2.34	%

Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	14.54%	Shs Outstand	35.12M	Perf Week	7.01%
Market Cap	337.85M	Forward P/E	61.40	EPS next Y	0.16	Insider Trans	1.56%	Shs Float	30.01M	Perf Month	-28.16%
Income	-14.21M	PEG	-	EPS next Q	-0.04	Inst Own	70.96%	Short Float / Ratio	20.35% / 8.88	Perf Quarter	-35.44%
Sales	114.17M	P/S	2.96	EPS this Y	-1.31%	Inst Trans	-4.61%	Short Interest	6.11M	Perf Half Y	-54.15%
Book/sh	2.16	P/B	4.46	EPS next Y	130.32%	ROA	-7.38%	Target Price	28.13	Perf Year	-22.36%
Cash/sh	2.10	P/C	4.57	EPS next 5Y	15.00%	ROE	-36.92%	52W Range	7.60 - 28.25	Perf YTD	-34.82%
Dividend	-	P/FCF	-	EPS past 5Y	3.03%	ROI	-5.37%	52W High	-65.95%	Beta	0.41
Dividend %	-	Quick Ratio	5.33	Sales past 5Y	28.85%	Gross Margin	69.78%	52W Low	26.58%	ATR	0.66
Employees	217	Current Ratio	5.80	Sales Q/Q	50.13%	Oper. Margin	3.09%	RSI (14)	39.26	Volatility	4.51% 6.63%
Optionable	Yes	Debt/Eq	2.50	EPS Q/Q	45.77%	Profit Margin	-12.44%	Rel Volume	0.52	Prev Close	9.40
Shortable	Yes	LT Debt/Eq	2.49	Earnings	Nov 13 AMC	Payout	-	Avg Volume	687.85K	Price	9.62
Recom	1.00	SMA20	-4.04%	SMA50	-23.62%	SMA200	-46.14%	Volume	354,607	Change	2.34%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-08-22	Resumed	B. Riley Securities	Buy	$17
Oct-14-21	Resumed	B. Riley Securities	Buy	$16
Sep-24-21	Initiated	Aegis Capital	Buy	$15
Jul-02-21	Initiated	Ladenburg Thalmann	Buy	$14.25

Nov-29-23 07:00AM	Harrow Completes Transfer of the TRIESENCE New Drug Application (Business Wire)
Nov-20-23 07:00AM	Harrow to Present at Two Investor Conferences in November (Business Wire) +5.58%
Nov-14-23 12:56PM	Harrow Health, Inc. (NASDAQ:HROW) Q3 2023 Earnings Call Transcript (Insider Monkey) -36.01%
Nov-13-23 05:07PM	Harrow Inc (HROW) Reports 50% Revenue Growth in Q3 2023 (GuruFocus.com)
04:01PM	Harrow Announces Third Quarter 2023 Financial Results (Business Wire)
08:00AM	Loading…
Oct-30-23 08:00AM	Harrow Will Release Third Quarter 2023 Financial Results on November 13, 2023 (Business Wire)
Oct-24-23 07:00AM	Harrow Completes Transfer of NDAs and Launches FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, and ZERVIATE in the U.S. (Business Wire)
Sep-29-23 08:00AM	Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. (Business Wire)
Sep-26-23 08:00AM	Melt Pharmaceuticals Announces Exclusive Development and License Agreement with Catalent for Its Zydis® Fast-Dissolve Technology for Use in MELT-300 for Needle- and Opioid-Free Procedural Sedation (Business Wire) -5.20%
Sep-21-23 01:03PM	Opaleye Management Inc. Reduces Stake in Harrow Health Inc. (GuruFocus.com)
Aug-11-23 01:05PM	Harrow Health, Inc. (NASDAQ:HROW) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:54AM	Q2 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) -15.45%
Aug-09-23 04:14PM	Harrow: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Harrow Announces Second Quarter 2023 Financial Results (Business Wire)
Jul-31-23 07:00AM	Harrow Launches VIGAMOX® in the U.S. (Business Wire)
02:56PM	Loading…
Jul-28-23 02:56PM	10 Best Small Cap Pharma Stocks to Buy (Insider Monkey)
Jul-26-23 03:42PM	Harrow Health inks deals for the rights to eight medications (American City Business Journals)
09:00AM	Harrow to Announce Second Quarter 2023 Financial Results on August 9, 2023 (Business Wire)
Jul-20-23 10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-19-23 12:17PM	Why Shares of Harrow Health Are Jumping Wednesday (Motley Fool) +17.84%
07:00AM	Harrow Prices $60 Million Public Offering of Common Stock (Business Wire)
Jul-18-23 05:00PM	Harrow Acquires Santens Branded Ophthalmic Portfolio (Business Wire)
04:05PM	Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance (Business Wire)
04:04PM	Harrow Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq (Business Wire)
Jul-05-23 06:15PM	Harrow Health (HROW) Gains As Market Dips: What You Should Know (Zacks)
Jun-29-23 06:15PM	Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know (Zacks)
Jun-23-23 06:15PM	Harrow Health (HROW) Flat As Market Sinks: What You Should Know (Zacks)
Jun-16-23 06:00PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
May-17-23 08:00AM	Harrow to Participate in B. Riley Securities 23rd Annual Institutional Investor Conference on May 24, 2023 (Business Wire)
11:57AM	Loading…
May-16-23 11:57AM	Harrow Health, Inc. (NASDAQ:HROW) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-15-23 11:21AM	Analysts Initiate Coverage: 5 Stocks for Higher Returns (Zacks) -5.22%
May-12-23 01:48PM	Why Shares of Harrow Health Are Slumping Friday (Motley Fool) -18.58%
06:26AM	Q1 2023 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 05:15PM	Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:29PM	Harrow: Q1 Earnings Snapshot (AP Finance)
04:01PM	Harrow Announces First Quarter 2023 Financial Results (Business Wire)
May-08-23 12:07PM	Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing? (Zacks)
May-04-23 08:00AM	Harrow to Launch FDA-Approved IHEEZO at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting (Business Wire)
04:59AM	Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta (Zacks)
May-03-23 06:44AM	5 Stocks With Recent Price Strength That Still Have Upside (Zacks)
May-02-23 04:42PM	Use New Analyst Coverage to Find Great Momentum Stocks to Buy in May (Zacks)
09:40AM	Is HCA Healthcare (HCA) Outperforming Other Medical Stocks This Year? (Zacks)
07:00AM	Harrow Launches ILEVRO®, NEVANAC®, and MAXIDEX® in the U.S. (Business Wire)
May-01-23 08:50AM	Here's Why Momentum in Harrow (HROW) Should Keep going (Zacks)
Apr-28-23 06:00PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
05:00AM	Zacks.com featured highlights Harrow Health and Disc Medicine Opco (Zacks)
Apr-27-23 08:05AM	2 Stocks in Focus as Analysts Initiate Coverage (Zacks)
08:00AM	Harrow to Announce First Quarter 2023 Financial Results on May 11, 2023 (Business Wire)
Apr-24-23 08:43AM	Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day (Zacks)
07:09AM	Bull Of The Day: Harrow Health (HROW) (Zacks)
Apr-20-23 08:31AM	5 Small Hidden Gems to Pick From a Rangebound Wall Street (Zacks)
Apr-19-23 06:15PM	Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know (Zacks)
08:31AM	Zacks.com featured highlights include Riley Exploration Permian, Harrow Health, Crawford, Tecnoglass and Lantheus Holdings (Zacks)
Apr-18-23 06:24AM	5 Stocks With Recent Price Strength to Maximize Your Gains (Zacks)
Apr-14-23 08:50AM	Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength (Zacks)
Apr-13-23 06:15PM	Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know (Zacks)
Apr-12-23 09:40AM	Are Medical Stocks Lagging Fulgent Genetics (FLGT) This Year? (Zacks)
Apr-09-23 04:04PM	A New Roster of Top Stock-Fund Managers (The Wall Street Journal)
Apr-05-23 09:34AM	4 Medical Stocks to Buy as Rate Hike Cycle Nears End (Zacks)
Apr-04-23 05:37AM	Zacks.com featured highlights Bellerophon Therapeutics, Crawford, Riley Exploration Permian, Harrow Health and Lantheus (Zacks)
Apr-03-23 06:53AM	5 Stocks With Recent Price Strength Amid March Rally (Zacks)
Mar-29-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Mar-28-23 02:59PM	B. Riley Leads Financing to Support Harrow Health Acquisition (PR Newswire)
07:00AM	Harrow Announces New $100 Million Secured Credit Facility with Oaktree (Business Wire)
Mar-27-23 08:51AM	Harrow Health, Inc. (NASDAQ:HROW) Q4 2022 Earnings Call Transcript (Insider Monkey) +16.50%
Mar-24-23 05:42AM	Q4 2022 Harrow Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.78%
Mar-23-23 04:06PM	Harrow Announces Fourth Quarter and Year-End 2022 Financial Results (Business Wire)
Mar-13-23 07:00AM	Harrow Announces Transitional Pass-Through Reimbursement Status for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% (Business Wire)
Mar-06-23 08:00AM	Harrow Announces Appointment of Mark Mannebach, Ph.D., R.Ph. as Head of Regulatory Affairs and Pharmacovigilance (Business Wire)
Mar-02-23 08:00AM	Harrow to Announce Fourth Quarter 2022 Financial Results on March 23, 2023 (Business Wire)
Feb-16-23 06:42AM	Is Harrow Health (HROW) an Undervalued Stock? (Insider Monkey) +5.41%
Feb-15-23 07:00AM	Harrow Launches Next-Generation Compounded Atropine Formulations (Business Wire)
Feb-03-23 08:50AM	Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable (Zacks) +8.29%
Feb-02-23 06:30AM	Harrow Announces Permanent, Product-Specific J-Code (J2403) for IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia Effective April 1, 2023 (Business Wire) +6.53%
Jan-23-23 07:00AM	Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products (Business Wire)
Jan-21-23 07:33AM	Investing in Harrow Health (NASDAQ:HROW) five years ago would have delivered you a 752% gain (Simply Wall St.)
Jan-18-23 08:50AM	Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why (Zacks)
Jan-05-23 07:00AM	Harrow Announces Availability of Fortisite Formulations for In-Office Use (Business Wire)
Dec-25-22 07:24AM	Trade Alert: The CEO & Chairman of the Board Of Harrow Health, Inc. (NASDAQ:HROW), Mark Baum, Has Just Spent US$335k Buying 1.8% More Shares (Simply Wall St.)
Dec-21-22 09:21AM	Melt Pharmaceuticals MELT-300 (Midazolam 3mg and Ketamine 50mg Sublingual Tablet) Achieves Primary Sedation Endpoint in Phase 2 Pivotal Efficacy and Safety Study (Business Wire) +10.57%
Dec-16-22 07:00AM	Harrow Secures Capital to Close Recently Announced Acquisition (Business Wire)
Dec-14-22 03:24PM	Harrow Health inks $175 million deal for the rights to five medications (American City Business Journals) +15.05%
09:41AM	Harrow Health Acquires Rights To Novartis' Five Approved Ophthalmic Products (Benzinga)
06:32AM	Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and "BB" Rating from Egan-Jones (Business Wire)
06:31AM	Harrow Prices $25 Million Offering (Business Wire)
06:30AM	Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® (Business Wire)
Nov-30-22 08:00AM	Harrow and iOR Partners Expand National Product Supply Agreement (Business Wire)
Nov-16-22 05:06AM	Harrow Health Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.) -5.60%
Nov-14-22 04:05PM	Harrow Announces Third Quarter 2022 Financial Results (Business Wire)
Nov-10-22 08:00AM	Harrow Launches Atropine.com (Business Wire)
Oct-28-22 08:00AM	Harrow to Announce Third Quarter 2022 Financial Results on November 14, 2022 (Business Wire)
Oct-27-22 08:00AM	Melt Pharmaceuticals Announces Dosing of Last Patient in Phase 2 Pivotal Efficacy and Safety Study for MELT-300 (Business Wire)
Oct-13-22 09:35AM	Harrow Health, Inc. (NASDAQ:HROW) has caught the attention of institutional investors who hold a sizeable 48% stake (Simply Wall St.)
Oct-06-22 03:23PM	Harrow Health sells part of company for up to $10.5 million (American City Business Journals)
Oct-05-22 05:35PM	Harrow Sells Non-Ophthalmic Compounding Business (Business Wire)
Sep-29-22 07:00AM	ImprimisRx Launches Fortisite (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation (Business Wire) +16.25%
Sep-28-22 07:09AM	FDA Approves First Branded Ocular Anesthetic In Almost 14 Years (Benzinga)
Sep-27-22 01:50PM	Harrow Announces U.S. FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia (Business Wire) +27.86%
Sep-21-22 06:01PM	Melt Pharmaceuticals files for IPO (MarketWatch)

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAUM MARK L	Chief Executive Officer	Nov 16	Buy	8.11	7,500	60,825	2,022,961	Nov 16 04:45 PM
Opaleye Management Inc.	10% Owner	Nov 15	Buy	8.03	25,000	200,735	3,645,000	Nov 16 04:05 PM
Opaleye Management Inc.	10% Owner	Sep 20	Buy	14.49	5,983	86,710	3,620,000	Sep 20 06:39 PM
Opaleye Management Inc.	10% Owner	Sep 19	Buy	14.65	14,017	205,366	3,614,017	Sep 20 06:39 PM
Makary Martin A.	Director	Aug 14	Buy	16.92	20,000	338,400	45,000	Aug 15 07:30 AM
BAUM MARK L	Chief Executive Officer	Aug 14	Buy	17.05	5,800	98,890	2,015,461	Aug 15 07:30 AM
BAUM MARK L	Chief Executive Officer	Apr 03	Option Exercise	8.99	180,000	1,618,200	1,664,962	Apr 04 07:54 PM
BOLL ANDREW R.	Chief Financial Officer	Mar 31	Option Exercise	6.00	90,000	540,000	358,461	Apr 04 07:50 PM
BAUM MARK L	Chief Executive Officer	Dec 22	Buy	13.39	25,000	334,750	1,432,141	Dec 23 07:03 AM
BOLL ANDREW R.	Chief Financial Officer	Dec 22	Buy	13.54	2,500	33,850	255,063	Dec 23 07:02 AM
Van Horn R. Lawrence	Director	Dec 22	Buy	13.42	1,860	24,961	1,860	Dec 23 07:00 AM
Makary Martin A.	Director	Dec 21	Buy	13.37	25,000	334,250	25,000	Dec 23 07:01 AM
Opaleye Management Inc.	10% Owner	Dec 14	Buy	10.52	431,183	4,536,045	3,600,000	Dec 14 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HROW

Harrow Inc

Upgrade your FINVIZ experience